Benzodiazepine Drugs Market is Expected to Expand at a CAGR of 2.7% from 2018 to 2026

Transparency Market Research (TMR) has published a new report titled, "Benzodiazepine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". According to the report, the global benzodiazepine drugs market was valued at US $ 2,057.19 Mn in 2017.

Report Overview @

https://www.transparencymarketresearch.com/benzodiazepine-drugs-market.html

It is projected to expand at a CAGR of 2.7% between 2018 and 2026. The benzodiazepine drugs market is projected to expand during the forecast period owing to the rise in prevalence of anxiety, seizures, and increase in concerns among people about preventive measures for stress-related conditions. Moreover, higher prescriptions for benzodiazepine drugs, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are propelling the global benzodiazepine drugs market. North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals for benzodiazepine drugs in the region. Latin America and Asia Pacific are potential markets for benzodiazepine drugs. The market in Asia Pacific is projected to expand at a CAGR of 3.5% during the forecast period.

Increase in prevalence of anxiety disorders, insomnia, seizures and comparatively higher number of prescriptions for benzodiazepines to drive the global market

Planning To Lay Down Future Strategy? Request Brochure Of Benzodiazepine Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28424

Rise in prevalence of anxiety and seizures is a major driver of the global benzodiazepine drugs market. Current lifestyle and urban life have made peoples' lives more stressful, which leads to mental disorders such as depression, anxiety, panic, and maniac conditions. Psychoactive drugs, such as benzodiazepine, are required to relieve these conditions and attacks. For instance, according to WHO, in 2015, the total number of people living with anxiety disorders, globally, was 264 million. Similarly, higher number of prescriptions for benzodiazepines, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are major drivers of the global benzodiazepine drugs market.

Alprazolam to be highly lucrative segment

Alprazolam is expanding segment of the benzodiazepine drugs market. It is projected to account for 29.35% share of the market, and expand at a CAGR of 2.9%, during the forecast period. The segment is anticipated to reach a value of US$ 768.09 Mn by 2026. Extensive utilization of Alprazolam in anxiety and panic disorders and higher number of prescriptions of Alprazolam for these conditions are likely to drive the segment of the global market during the forecast period.

Anxiety to be dominant segment

Anxiety was a dominant segment of the global benzodiazepine drugs market in 2017. It is expected to maintain its position during the forecast period. The segment is anticipated to reach a value of US$ 1,384.12 Mn by 2026. It is projected to account for 52.9% share of the market and expand at a CAGR of 3.1% during the forecast period. Benzodiazepine drugs are preferred to control the symptoms and general anxiety. Therefore, a rise in the prevalence of anxiety across the globe drives the segment. For instance, according to Anxiety and Depression Association of America (ADAA), around 40 million adults are affected every year with anxiety disorders, of which only 36.9% receive treatment.

To Obtain All-Inclusive Information On Forecast Analysis Of Benzodiazepine Drugs Market , Request A Discount
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28424

Ultra-short Acting to be promising segment

In terms of time of action, the global market has been segmented into ultra-short acting, short acting, and long acting. The short acting segment held a major share of the global market in 2017. It is projected to maintain its leading position in the market during the forecast period. The short acting segment is projected to hold 77.1% share of the market by 2026. However, the ultra-short acting segment is anticipated to expand at a CAGR of 3.1% during the forecast period. Expansion of the segment can be attributed to the rise in popularity due to its pharmacokinetic activity and less chance for developing drug dependency.

Others distribution channel to be promising segment

In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies and others. The retail pharmacies segment held a major share of the global market in 2017. It is estimated to maintain its position in the global market during the forecast period. The retail pharmacies segment is projected to hold 54.12% share of the market and expand at a CAGR of 2.8% during the forecast period. However, the others segment, which includes online pharmacies and mail pharmacies, is highly lucrative. It is expected to expand at a higher CAGR of 3.0% during the forecast period owing to better discount rates on online platforms and popularity owing to convenience.

North America expected to dominate global market

In terms of region, the global benzodiazepine drugs market has been segmented into five major regions as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The market in North America is likely to expand at a CAGR of 2.2% during the forecast period. The market in North America was valued at US$ 781.73 Mn, and the region accounted for 38.0% share of the global market, in 2017.

This was due to the rise in prevalence of anxiety, panic disorders, and higher FDA approvals for benzodiazepine drugs by major players in the region. The anxiety segment dominated the market in the region. It is projected to expand at a CAGR of 2.6% during the same period. Asia Pacific is a highly lucrative market. It is anticipated to expand at a CAGR of 3.5% during the forecast period due to a rise in the prevalence of anxiety disorders, seizures, increased awareness among people about healthcare, and rise in health care expenditure in the region.

Pfizer Inc. and F.Hoffmann La Roche Ltd. among major players in global market

The global benzodiazepine drugs market is fragmented in terms of number of players. Key players operating in the global market include Pfizer Inc., F.Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan, N.V., Teva Pharmaceutical Industries Ltd. and H.Lundbeck A/S. More FDA approvals are received by these major players in North America for benzodiazepine drugs.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.

This release was published on openPR.